Core Insights - Elicio Therapeutics, Inc. has granted 5,400 inducement stock options to two new employees as part of their employment agreement, in compliance with Nasdaq Listing Rule 5635(c)(4) [1] - The stock options were approved by the Compensation Committee and are part of the 2024 Inducement Incentive Award Plan [1] - The stock options will vest over four years, with 25% vesting on the first anniversary of each employee's start date and the remainder vesting monthly thereafter, contingent on continued service [6] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment [13] - The company utilizes AMP technology to deliver therapeutic payloads directly to lymph nodes, enhancing the immune system's ability to fight cancer [13] - Elicio's lead product candidate, ELI-002, targets mKRAS-driven cancers and is currently in clinical trials [12][7] Product Pipeline - ELI-002 is being studied in two ongoing clinical trials: AMPLIFY-201 for high relapse risk mKRAS-driven solid tumors and AMPLIFY-7P for mKRAS-driven pancreatic cancer [7] - The ELI-002 7P formulation aims to provide immune response coverage against seven common KRAS mutations, potentially increasing the patient population [7]
Elicio Therapeutics Reports Inducement Grants